A series of setbacks almost caused the demise of PARP inhibitors, but four companies are now beginning pivotal trials of these agents in breast and ovarian cancer.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Proteome-wide identification of the endogenous ADP-ribosylome of mammalian cells and tissue
Nature Communications Open Access 30 September 2016
-
Single cell resolution in vivo imaging of DNA damage following PARP inhibition
Scientific Reports Open Access 18 May 2015
-
Tackling the tumor microenvironment: what challenge does it pose to anticancer therapies?
Protein & Cell Open Access 05 September 2014
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
PowerPoint slides
Rights and permissions
About this article
Cite this article
Garber, K. PARP inhibitors bounce back. Nat Rev Drug Discov 12, 725–727 (2013). https://doi.org/10.1038/nrd4147
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4147
This article is cited by
-
Proteome-wide identification of the endogenous ADP-ribosylome of mammalian cells and tissue
Nature Communications (2016)
-
Single cell resolution in vivo imaging of DNA damage following PARP inhibition
Scientific Reports (2015)
-
European regulators approve first PARP inhibitor
Nature Reviews Drug Discovery (2014)
-
PARP inhibitors and IR join forces to strike glioblastoma-initiating cells
Cell Death & Differentiation (2014)
-
Tackling the tumor microenvironment: what challenge does it pose to anticancer therapies?
Protein & Cell (2014)